https://www.pharmaradar360.com/article/rhelion-subsidiary-supplies-psilocybin-for-phase-3-palliative-care-trial-0d4d220a9ee9c49ePharmaRadar360en2026-09-21T12:11:57.000ZRhelion Subsidiary Supplies Psilocybin for Phase 3 Palliative Care Trialhttps://www.pharmaradar360.com/article/denmark-eyes-shortage-substitution-protocols-as-industry-urges-tight-limits-d1dc310ade3ee8dePharmaRadar360en2026-09-21T12:10:50.000ZDenmark eyes shortage substitution protocols as industry urges tight limitshttps://www.pharmaradar360.com/article/covid-19-vaccine-5-years-and-over-pgd-and-vgd-6776102a716b3a92PharmaRadar360en2026-09-21T12:10:31.000ZCOVID-19 vaccine (5 years and over) PGD and VGDhttps://www.pharmaradar360.com/article/filament-ships-psilocybin-drug-pex010-for-phase-3-trial-on-psychological-distres-00504eb35086a553PharmaRadar360en2026-09-21T12:03:26.000ZFilament ships psilocybin drug PEX010 for Phase 3 trial on psychological distress in palliative care.https://www.pharmaradar360.com/article/weight-loss-drug-developers-line-up-to-tap-lucrative-market-as-competition-heats-54efba15b344cc0fPharmaRadar360en2026-09-21T12:01:24.000ZWeight-loss drug developers line up to tap lucrative market as competition heats uphttps://www.pharmaradar360.com/article/caplyta-lumateperone-shows-significant-and-rapid-improvement-in-bipolar-mania-in-14963d1b5f3d3bc5PharmaRadar360en2026-09-21T12:00:00.000ZCAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 studyhttps://www.pharmaradar360.com/article/trump-s-drug-price-plan-targets-foreign-freeloaders-but-shoots-american-innovato-5e14093c8aaa4a87PharmaRadar360en2026-09-21T12:00:00.000ZTrump’s drug price plan targets foreign freeloaders — but shoots American innovatorshttps://www.pharmaradar360.com/article/abbvie-and-iambic-announce-collaboration-to-accelerate-ai-driven-drug-discovery-6b060a185e233d47PharmaRadar360en2026-09-21T12:00:00.000ZAbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discoveryhttps://www.pharmaradar360.com/article/beyond-clinical-endpoints-rethinking-als-drug-development-through-disease-biolog-b7cd7818b37e9411PharmaRadar360en2026-09-21T11:58:09.000ZBeyond clinical endpoints: Rethinking ALS drug development through disease biologyhttps://www.pharmaradar360.com/article/psilocybin-doses-without-hallucinations-will-be-tested-in-end-of-life-care-6c1213d2afac37aePharmaRadar360en2026-09-21T11:49:00.000ZPsilocybin doses without hallucinations will be tested in end-of-life carehttps://www.pharmaradar360.com/article/virtual-biotech-employs-37-000-ai-agents-for-end-to-end-drug-development-8f7d97a93a576cdcPharmaRadar360en2026-09-21T11:46:42.000ZVirtual Biotech "Employs" 37,000 AI Agents for End-to-End Drug Developmenthttps://www.pharmaradar360.com/article/cyllene-appoints-seasoned-biotech-exec-as-cfo-74f91b753010fd2cPharmaRadar360en2026-09-21T11:40:15.000ZCyllene appoints seasoned biotech exec as CFOhttps://www.pharmaradar360.com/article/pharma-exports-continue-to-strengthen-the-swedish-economy-6d1e9ae333cb8b5fPharmaRadar360en2026-09-21T11:37:30.000ZPharma exports continue to strengthen the Swedish economyhttps://www.pharmaradar360.com/article/la-ema-y-hma-abren-el-proceso-de-comentarios-sobre-la-nueva-guia-de-eu-in-para-i-b9a7929b040a0936PharmaRadar360en2026-09-21T11:26:32.000ZLa EMA y HMA abren el proceso de comentarios sobre la nueva guía de EU-IN para investigadoreshttps://www.pharmaradar360.com/article/karnataka-minister-says-pfizer-c-f-agency-failed-to-aid-fake-drug-probe-d544ad166f836728PharmaRadar360en2026-09-21T11:23:03.000ZKarnataka Minister says Pfizer C&F agency failed to aid fake drug probehttps://www.pharmaradar360.com/article/brazil-pharmaceutical-distributors-face-mounting-financial-pressure-38f80a8bb2b236cePharmaRadar360en2026-09-21T11:20:54.000ZBrazil pharmaceutical distributors face mounting financial pressurehttps://www.pharmaradar360.com/article/sichuan-biokin-pharmaceutical-s-unit-receives-milestone-payment-from-bristol-mye-ca99112d5b22276bPharmaRadar360en2026-09-21T11:16:29.000ZSichuan Biokin Pharmaceutical's Unit Receives Milestone Payment From Bristol-Myers Squibbhttps://www.pharmaradar360.com/article/serbian-biotech-startup-takes-its-journey-from-belgrade-to-cambridge-with-docume-4e3af3cef35b6b21PharmaRadar360en2026-09-21T11:02:40.000ZSerbian Biotech Startup Takes Its Journey from Belgrade to Cambridge with Documentary on Longevity Sciencehttps://www.pharmaradar360.com/article/serbian-biotech-startup-takes-its-journey-from-belgrade-to-cambridge-with-docume-993c912068e3ffbePharmaRadar360en2026-09-21T11:02:36.000ZSerbian Biotech Startup Takes Its Journey from Belgrade to Cambridge with Documentary on Longevity Sciencehttps://www.pharmaradar360.com/article/tiziana-announces-last-patient-completes-last-visit-in-phase-2a-inform-ms-trial-121aeb1f6cd0e04cPharmaRadar360en2026-09-21T11:00:00.000ZTiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumabhttps://www.pharmaradar360.com/article/how-inline-refractive-index-monitoring-can-improve-real-time-peptide-manufacturi-6daaaf2be2a7405bPharmaRadar360en2026-09-21T10:54:35.000ZHow inline refractive index monitoring can improve real-time peptide manufacturinghttps://www.pharmaradar360.com/article/singapore-draws-international-biotech-vcs-as-asia-pacific-life-sciences-sector-t-8b267d226e97ee94PharmaRadar360en2026-09-21T10:53:07.000ZSingapore draws international biotech VCs as Asia-Pacific life sciences sector takes offhttps://www.pharmaradar360.com/article/hansoh-pharmaceutical-group-co-ltd-to-go-ex-dividend-on-september-22nd-2026-with-7e95578a30c6b612PharmaRadar360en2026-09-21T10:48:19.000ZHANSOH PHARMACEUTICAL GROUP CO LTD To Go Ex-Dividend On September 22nd, 2026 With 0.03659 USD Dividend Per Sharehttps://www.pharmaradar360.com/article/merck-s-keytruda-qlextm-pembrolizumab-and-berahyaluronidase-alfa-pmph-approved-i-cb6eee590ac0416cPharmaRadar360en2026-09-21T10:45:00.000ZMerck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japanhttps://www.pharmaradar360.com/article/teva-nyse-teva-legal-chief-files-273k-share-sale-notice-e62f1c4bffd47859PharmaRadar360en2026-09-21T10:40:50.000ZTeva (NYSE: TEVA) legal chief files $273K share-sale noticehttps://www.pharmaradar360.com/article/the-fda-has-approved-29-u-k-led-cancer-drugs-since-2021-now-a-u-k-regulator-will-a64efa1f5f19d8b7PharmaRadar360en2026-09-21T10:30:00.000ZThe FDA has approved 29 U.K.-led cancer drugs since 2021. Now a U.K. regulator will lead OS Therapies’ review.https://www.pharmaradar360.com/article/lilly-secures-full-fda-nod-for-inluriyo-verzenio-breast-cancer-combo-986279ff4c2ee3b2PharmaRadar360en2026-09-21T10:29:49.000ZLilly secures full FDA nod for Inluriyo-Verzenio breast cancer combohttps://www.pharmaradar360.com/article/novo-buys-three-non-incretin-obesity-programs-from-kallyope-1771b5edb75f4697PharmaRadar360en2026-09-21T10:29:14.000ZNovo buys three non-incretin obesity programs from Kallyopehttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-older-adults-vaccination-coverage-in-england-aug-16bd5e27d65a23b1PharmaRadar360en2026-09-21T10:28:57.000ZRespiratory syncytial virus (RSV) older adults vaccination coverage in England: August 2026https://www.pharmaradar360.com/article/medicines-apply-for-a-variation-to-your-marketing-authorisation-2a4014b9e82727c7PharmaRadar360en2026-09-21T10:28:18.000ZMedicines: apply for a variation to your marketing authorisationhttps://www.pharmaradar360.com/article/major-reform-of-eu-drug-regulations-what-will-change-for-patients-1b494b7bc3bbb314PharmaRadar360en2026-09-21T10:25:11.000ZMajor Reform of EU Drug Regulations: What Will Change for Patientshttps://www.pharmaradar360.com/article/metavallon-backs-parkinson-s-biotech-anacalypsis-in-first-of-its-kind-greek-deal-a0596c80e643d916PharmaRadar360en2026-09-21T10:14:29.000ZMetavallon backs Parkinson's biotech Anacalypsis in first-of-its-kind Greek dealhttps://www.pharmaradar360.com/article/research-collaboration-to-advance-a-novel-therapy-for-alzheimer-s-disease-f02f2d6a6aefabfcPharmaRadar360en2026-09-21T10:09:33.000ZResearch collaboration to advance a novel therapy for Alzheimer’s diseasehttps://www.pharmaradar360.com/article/karnataka-busts-fake-drug-racket-pfizer-depot-7-other-firms-face-licence-suspens-3be6e17a0c46130aPharmaRadar360en2026-09-21T10:09:26.000ZKarnataka Busts Fake Drug Racket: Pfizer Depot, 7 Other Firms Face Licence Suspensionhttps://www.pharmaradar360.com/article/xenon-stock-craters-30-on-drug-trial-setback-its-failure-could-be-this-biotech-s-56a2fa84d3bb02c3PharmaRadar360en2026-09-21T10:03:40.000ZXenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain.https://www.pharmaradar360.com/article/cannabinoids-vs-opioids-is-chronic-pain-treatment-at-a-turning-point-6360efc5a5b20214PharmaRadar360en2026-09-21T10:00:34.000ZCannabinoids vs Opioids: Is Chronic Pain Treatment at a Turning Point?https://www.pharmaradar360.com/article/high-tide-of-china-biotech-deals-seen-as-us-curb-fears-fade-analysts-aaba7a319c133b2cPharmaRadar360en2026-09-21T10:00:10.000Z‘High tide’ of China biotech deals seen as US curb fears fade: analystshttps://www.pharmaradar360.com/article/pharma-and-biotech-industry-audit-services-for-gmp-gxp-and-supplier-compliance-2ecc2a1cefcf64f8PharmaRadar360en2026-09-21T09:58:14.000ZPharma and biotech industry audit services for GMP, GxP and supplier compliancehttps://www.pharmaradar360.com/article/adult-social-care-finance-report-england-2025-to-2026-edfdf55f46596236PharmaRadar360en2026-09-21T09:52:28.000ZAdult social care finance report, England: 2025 to 2026https://www.pharmaradar360.com/article/adult-social-care-activity-report-england-2025-to-2026-d04cfc1369caa66dPharmaRadar360en2026-09-21T09:52:21.000ZAdult social care activity report, England: 2025 to 2026https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-43-report-data-to-week-42-dat-99cbb355a95c8f35PharmaRadar360en2026-09-21T09:51:42.000ZNational flu and COVID-19 surveillance report, week 43 report: data to week 42 (data up to 18 October 2026)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-18-october-2026-673a62d4be0d46e6PharmaRadar360en2026-09-21T09:51:35.000ZWeekly all-cause mortality surveillance: week ending 18 October 2026https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-43-report-data-to-week-42-data-up-t-d32e68d6017bb7c3PharmaRadar360en2026-09-21T09:51:27.000ZNational Norovirus and Rotavirus Report, week 43 report: data to week 42 (data up to 18 October 2026)https://www.pharmaradar360.com/article/cold-mortality-monitoring-report-england-winter-2025-to-2026-625b82782f2a1916PharmaRadar360en2026-09-21T09:51:19.000ZCold mortality monitoring report, England: winter 2025 to 2026https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-39-report-data-to-week-38-data-up-t-b701a0f0114ed05cPharmaRadar360en2026-09-21T09:50:07.000ZNational Norovirus and Rotavirus Report, week 39 report: data to week 38 (data up to 20 September 2026)https://www.pharmaradar360.com/article/d-d-pharmatech-s-head-of-r-d-park-eun-ji-newco-bridges-early-stage-biotech-firms-b72d729bb82a03d9PharmaRadar360en2026-09-21T09:45:05.000ZD&D Pharmatech’s Head of R&D Park Eun-ji,: “NewCo bridges early-stage biotech firms and big pharma”https://www.pharmaradar360.com/article/belgium-s-novadip-biosciences-raises-10-4-million-to-fund-pivotal-clinical-trial-1c00f7f63d3d96abPharmaRadar360en2026-09-21T09:40:43.000ZBelgium's Novadip Biosciences raises €10.4 million to fund pivotal clinical trial and unlock EIB loan tranchehttps://www.pharmaradar360.com/article/thousands-invited-to-register-for-public-panel-for-independent-commission-on-adu-52b360f1b8267410PharmaRadar360en2026-09-21T09:35:00.000ZThousands invited to register for Public Panel for Independent Commission on Adult Social Carehttps://www.pharmaradar360.com/article/3-chinese-biopharma-stocks-retail-investors-are-watching-for-licensing-deals-f9c5948024fb39f8PharmaRadar360en2026-09-21T09:24:08.000Z3 Chinese Biopharma Stocks Retail Investors Are Watching For Licensing Dealshttps://www.pharmaradar360.com/article/why-ultragenyx-pharmaceutical-inc-nasdaq-rare-is-in-focus-now-2794a473faf0e70fPharmaRadar360en2026-09-21T09:24:00.000ZWhy Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Is In Focus Now?https://www.pharmaradar360.com/article/sarepta-therapeutics-srpt-stock-analysis-navigating-the-biotech-waters-with-a-fo-00f2039c62c0d646PharmaRadar360en2026-09-21T09:22:40.000ZSarepta Therapeutics (SRPT) Stock Analysis: Navigating the Biotech Waters with a Forward P/E of 7.64https://www.pharmaradar360.com/article/legend-biotech-corporation-legn-stock-analysis-unveiling-a-175-potential-upside-bcd9d089c6ca5a63PharmaRadar360en2026-09-21T09:22:01.000ZLegend Biotech Corporation (LEGN) Stock Analysis: Unveiling a 175% Potential Upside in Biotech Innovationhttps://www.pharmaradar360.com/article/krystal-biotech-inc-krys-stock-analysis-a-look-at-its-14-36-potential-upside-9a61874672731d38PharmaRadar360en2026-09-21T09:21:09.000ZKrystal Biotech, Inc. (KRYS) Stock Analysis: A Look At Its 14.36% Potential Upsidehttps://www.pharmaradar360.com/article/exelixis-inc-exel-stock-analysis-navigating-biotech-with-strong-revenue-growth-a-5788861c9117fa48PharmaRadar360en2026-09-21T09:21:08.000ZExelixis, Inc. (EXEL) Stock Analysis: Navigating Biotech with Strong Revenue Growth and Strategic Collaborationshttps://www.pharmaradar360.com/article/nuvalent-inc-nuvl-stock-analysis-navigating-the-biotech-landscape-with-a-clinica-7e778788f7bae560PharmaRadar360en2026-09-21T09:20:50.000ZNuvalent, Inc. (NUVL) Stock Analysis: Navigating the Biotech Landscape with a Clinical Focushttps://www.pharmaradar360.com/article/analysts-extremely-bullish-as-telix-beams-into-novartis-territory-with-1-6b-itm-130dcd4d2d8d5288PharmaRadar360en2026-09-21T09:19:06.000ZAnalysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisitionhttps://www.pharmaradar360.com/article/meningococcal-disease-enhanced-surveillance-form-969ec8a257418767PharmaRadar360en2026-09-21T09:15:58.000ZMeningococcal disease: enhanced surveillance formhttps://www.pharmaradar360.com/article/mycoplasma-genitalium-antimicrobial-resistance-surveillance-mars-8b728d0038ccd66fPharmaRadar360en2026-09-21T09:14:36.000ZMycoplasma genitalium antimicrobial resistance surveillance (MARS)https://www.pharmaradar360.com/article/ukhsa-commercial-opportunities-9e4f936a0befa657PharmaRadar360en2026-09-21T09:09:06.000ZUKHSA commercial opportunitieshttps://www.pharmaradar360.com/article/annual-flu-programme-8d7750db1c23f662PharmaRadar360en2026-09-21T09:06:32.000ZAnnual flu programmehttps://www.pharmaradar360.com/article/karnataka-suspends-pfizer-c-f-depot-licence-in-fake-drug-case-warns-consumers-ov-61ae4f712869af8fPharmaRadar360en2026-09-21T08:58:23.000ZKarnataka suspends Pfizer C&F Depot licence in fake drug case, warns consumers over suspicious labels and QR codeshttps://www.pharmaradar360.com/article/daewon-pharmaceutical-brings-shinbaro-in-house-to-expand-south-korea-osteoarthri-06deb3f19266a298PharmaRadar360en2026-09-21T08:51:00.000ZDaewon Pharmaceutical brings Shinbaro in-house to expand South Korea osteoarthritis push - CHOSUNBIZhttps://www.pharmaradar360.com/article/cue-chalks-up-phase-2-hives-win-for-xolair-challenger-dca24fea5b2e4874PharmaRadar360en2026-09-21T08:50:00.000ZCue chalks up phase 2 hives win for Xolair challengerhttps://www.pharmaradar360.com/article/karnataka-spurious-drugs-racket-fda-cancels-16-drug-licences-suspends-pfizer-c-f-583b24989cc671cePharmaRadar360en2026-09-21T08:49:18.000ZKarnataka Spurious Drugs Racket: FDA Cancels 16 Drug Licences, Suspends Pfizer C&F Depot in Bidadihttps://www.pharmaradar360.com/article/retension-and-lilly-backed-trex-bio-both-set-out-plans-to-join-biotech-ipo-stamp-d978dc40cc95aef6PharmaRadar360en2026-09-21T08:29:34.000ZRetension and Lilly-backed TRex Bio both set out plans to join biotech IPO stampedehttps://www.pharmaradar360.com/article/bofa-securities-lifts-sino-biopharmaceutical-target-to-hk-7-3-bullish-on-chinese-b25213c517e317dbPharmaRadar360en2026-09-21T08:26:00.000ZBofA Securities Lifts Sino Biopharmaceutical Target to HK$7.3, Bullish on Chinese Innovative Drug Globalization Momentumhttps://www.pharmaradar360.com/article/nykredit-a-s-takes-position-in-teva-pharmaceutical-industries-ltd-teva-8ef68b53d2f7b566PharmaRadar360en2026-09-21T08:12:45.000ZNykredit A S Takes Position in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/anthropic-bytedance-enter-ai-drug-discovery-the-next-coding-faces-critical-data-949e67c2cfec7bcbPharmaRadar360en2026-09-21T08:10:14.000ZAnthropic & ByteDance Enter AI Drug Discovery: The "Next Coding" Faces Critical Data Bottleneckshttps://www.pharmaradar360.com/article/aspen-achieves-top-10-ranking-for-integrated-reporting-excellence-11891286e263540bPharmaRadar360en2026-09-21T08:04:09.000ZAspen achieves Top 10 ranking for Integrated Reporting Excellencehttps://www.pharmaradar360.com/article/bidadi-fake-drug-racket-fallout-widens-karnataka-fda-cancels-16-licences-suspend-f5da6067ed6d5f34PharmaRadar360en2026-09-21T08:02:27.000ZBidadi Fake Drug Racket Fallout Widens: Karnataka FDA Cancels 16 Licences, Suspends 8 Including Pfizer Depothttps://www.pharmaradar360.com/article/buy-sun-pharmaceutical-industries-target-of-rs-2070-geojit-financial-services-05d4bece45133dbaPharmaRadar360en2026-09-21T08:01:41.000ZBuy Sun Pharmaceutical Industries; target of Rs 2070: Geojit Financial Serviceshttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-maternal-vaccination-coverage-in-england-may-202-2cc50be828051e6cPharmaRadar360en2026-09-21T07:54:02.000ZRespiratory syncytial virus (RSV) maternal vaccination coverage in England: May 2026https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-39-report-data-to-week-38-dat-1bbeb1fdd2fcb78dPharmaRadar360en2026-09-21T07:43:06.000ZNational flu and COVID-19 surveillance report, week 39 report: data to week 38 (data up to 20 September 2026)https://www.pharmaradar360.com/article/aston-university-joins-forces-with-biotech-firm-to-develop-realistic-human-skin-5439803eb98b58fbPharmaRadar360en2026-09-21T07:39:58.000ZAston University joins forces with biotech firm to develop realistic human skin modelshttps://www.pharmaradar360.com/article/south-korea-s-inventera-reports-phase-3-success-for-mri-contrast-agent-plans-reg-7e38950a6ba7475bPharmaRadar360en2026-09-21T07:35:00.000ZSouth Korea's Inventera Reports Phase 3 Success for MRI Contrast Agent, Plans Regulatory Filing This Yearhttps://www.pharmaradar360.com/article/china-plans-more-support-for-pharma-innovation-f77ec0948695270fPharmaRadar360en2026-09-21T07:09:45.000ZChina plans more support for pharma innovationhttps://www.pharmaradar360.com/article/phase-2-trial-suggests-vitamin-c-may-benefit-people-with-pre-cancer-blood-disord-64b38f62af9ca22ePharmaRadar360en2026-09-21T07:05:25.000ZPhase 2 trial suggests vitamin C may benefit people with pre-cancer blood disordershttps://www.pharmaradar360.com/article/inventera-s-mri-contrast-agent-passes-phase-3-trial-in-korea-22fdf31a869b455ePharmaRadar360en2026-09-21T06:53:52.000ZInventera's MRI Contrast Agent Passes Phase 3 Trial in Koreahttps://www.pharmaradar360.com/article/interview-mash-moves-beyond-clinical-graveyard-as-focus-shifts-to-targets-biomar-778863fe92e5aac3PharmaRadar360en2026-09-21T06:49:13.000Z[Interview] MASH moves beyond ‘clinical graveyard’ as focus shifts to targets, biomarkershttps://www.pharmaradar360.com/article/antengene-starts-phase-iii-clinch-3-trial-of-atg-022-in-advanced-gastric-cancer-02e84e96f3c002c3PharmaRadar360en2026-09-21T06:38:44.000ZAntengene Starts Phase III CLINCH-3 Trial of ATG-022 in Advanced Gastric Cancerhttps://www.pharmaradar360.com/article/lavengratinib-shows-100-response-rate-in-lowest-dose-achondroplasia-cohort-c1eaa9b89bb2e951PharmaRadar360en2026-09-21T06:38:39.000ZLavengratinib Shows 100% Response Rate in Lowest Dose Achondroplasia Cohorthttps://www.pharmaradar360.com/article/neurotech-international-initiates-phase-3-beyond-harmony-trial-with-first-patien-bc6f61556b31fc81PharmaRadar360en2026-09-21T06:20:13.000ZNeurotech International Initiates Phase 3 Beyond Harmony Trial with First Patient Dosed for Autism Treatmenthttps://www.pharmaradar360.com/article/is-aspen-betting-on-the-right-hiv-prevention-product-14903d010e56bd11PharmaRadar360en2026-09-21T06:19:50.000ZIs Aspen betting on the right HIV prevention product?https://www.pharmaradar360.com/article/copenhagen-biotech-takes-first-step-toward-european-approval-eyes-major-reformul-88ce2eac112529e9PharmaRadar360en2026-09-21T06:14:56.000ZCopenhagen biotech takes first step toward European approval, eyes major reformulation markethttps://www.pharmaradar360.com/article/cicc-cuts-alibaba-health-target-price-to-hk-4-5-bullish-on-pharmaceutical-busine-2ef4c2c59948d673PharmaRadar360en2026-09-21T05:25:00.000ZCICC Cuts Alibaba Health Target Price to HK$4.5, Bullish on Pharmaceutical Business Filling the Health Supplement Gaphttps://www.pharmaradar360.com/article/sunshine-guojian-pharmaceutical-co-ltd-xssc-688336-added-to-ftse-all-world-index-f7d596060f75cd57PharmaRadar360en2026-09-21T05:21:38.000ZSunshine Guojian Pharmaceutical Co., Ltd(XSSC: 688336) added to FTSE All-World Indexhttps://www.pharmaradar360.com/article/matica-bio-joins-hands-with-bondwell-for-protein-production-82d9ae6b6395045fPharmaRadar360en2026-09-21T05:10:01.000ZMatica Bio joins hands with Bondwell for protein productionhttps://www.pharmaradar360.com/article/cybin-eyes-q4-phase-3-data-for-depression-drug-hlp003-fe46f092d7c7b986PharmaRadar360en2026-09-21T05:02:56.000ZCybin Eyes Q4 Phase 3 Data for Depression Drug HLP003https://www.pharmaradar360.com/article/aluminum-pvc-blister-film-market-forecast-to-2035-pharmaceutical-demand-drives-5-953d6d97f21cf2cbPharmaRadar360en2026-09-21T05:01:10.000ZAluminum-PVC Blister Film Market Forecast to 2035: Pharmaceutical Demand Drives 5-7% CAGRhttps://www.pharmaradar360.com/article/biotech-week-ahead-xlv-beats-the-market-here-are-the-stocks-readouts-and-events-8162588003ba2afaPharmaRadar360en2026-09-21T04:37:00.000ZBiotech Week Ahead: XLV Beats The Market — Here Are The Stocks, Readouts And Events To Watch Nexthttps://www.pharmaradar360.com/article/north-china-pharmaceutical-company-ltd-xssc-600812-dropped-from-ftse-all-world-i-b96971880c9cd718PharmaRadar360en2026-09-21T04:35:49.000ZNorth China Pharmaceutical Company.Ltd(XSSC:600812) dropped from FTSE All-World Indexhttps://www.pharmaradar360.com/article/heilongjiang-zbd-pharmaceutical-co-ltd-xssc-603567-dropped-from-ftse-all-world-i-4353837e375a403aPharmaRadar360en2026-09-21T04:34:00.000ZHeilongjiang ZBD Pharmaceutical Co., Ltd.(XSSC:603567) dropped from FTSE All-World Indexhttps://www.pharmaradar360.com/article/should-phase-iii-diabetes-trial-start-require-action-from-uni-bio-science-shares-033cbff8c0320facPharmaRadar360en2026-09-21T04:28:17.000ZShould Phase III Diabetes Trial Start Require Action From Uni Bio Science Shares Investors?https://www.pharmaradar360.com/article/sansure-biotech-inc-xssc-688289-dropped-from-ftse-all-world-index-58517ea7bc89902ePharmaRadar360en2026-09-21T04:27:56.000ZSansure Biotech Inc.(XSSC: 688289) dropped from FTSE All-World Indexhttps://www.pharmaradar360.com/article/chinese-biopharma-stocks-jump-as-u-s-weighs-keeping-door-open-to-drug-deals-a80913ab3deb4527PharmaRadar360en2026-09-21T04:20:33.000ZChinese biopharma stocks jump as U.S. weighs keeping door open to drug dealshttps://www.pharmaradar360.com/article/china-resources-boya-bio-pharmaceutical-group-co-ltd-xsec-300294-dropped-from-ft-b7061d9fea7cd209PharmaRadar360en2026-09-21T04:11:28.000ZChina Resources Boya Bio-pharmaceutical Group Co.,Ltd(XSEC:300294) dropped from FTSE All-World Indexhttps://www.pharmaradar360.com/article/fda-warns-texas-beverage-companies-abou-acidified-food-unapproved-drug-claims-5909ec9e189f3706PharmaRadar360en2026-09-21T04:02:54.000ZFDA warns Texas beverage companies abou acidified food, unapproved drug claimshttps://www.pharmaradar360.com/article/fake-pfizer-labels-expired-vials-seized-karnataka-fda-cancels-16-licences-suspen-94d0597343aefd1ePharmaRadar360en2026-09-21T03:40:00.000ZFake Pfizer Labels, Expired Vials Seized: Karnataka FDA Cancels 16 Licences, Suspends 8 In Drug Racket Crackdownhttps://www.pharmaradar360.com/article/matica-bio-to-expand-into-protein-process-development-with-us-bondwell-999cb539da410badPharmaRadar360en2026-09-21T03:26:10.000ZMatica Bio to expand into protein process development with US Bondwellhttps://www.pharmaradar360.com/article/celltrion-wins-ema-approval-to-modify-phase-3-trial-for-darzalex-biosimilar-ct-p-b83c8c64d39982d8PharmaRadar360en2026-09-21T03:25:31.000ZCelltrion Wins EMA Approval to Modify Phase 3 Trial for Darzalex Biosimilar CT-P44https://www.pharmaradar360.com/article/shenqi-pharmaceutical-share-price-skyrockets-160-the-stock-is-truly-magical-2c0bba098ab6dc55PharmaRadar360en2026-09-21T03:14:55.000ZShenqi Pharmaceutical Share Price Skyrockets 160% – The Stock Is Truly "Magical"https://www.pharmaradar360.com/article/nyrada-raises-fresh-capital-to-fund-xolatryp-phase-iia-and-pipeline-expansion-4c148b1b6b22f576PharmaRadar360en2026-09-21T03:10:46.000ZNyrada Raises Fresh Capital to Fund Xolatryp Phase IIa And Pipeline Expansionhttps://www.pharmaradar360.com/article/kolon-tissuegene-ceo-noh-moon-jong-steps-down-after-tg-c-phase-3-failure-93ba35e01c4a0a62PharmaRadar360en2026-09-21T02:55:00.000ZKolon TissueGene CEO Noh Moon-jong Steps Down After TG-C Phase 3 Failurehttps://www.pharmaradar360.com/article/karnataka-fda-cancels-16-suspends-8-drug-licences-in-counterfeit-medicine-crackd-f0e2dfff72f4bb07PharmaRadar360en2026-09-21T02:27:00.000ZKarnataka FDA cancels 16, suspends 8 drug licences in counterfeit medicine crackdown | India Newshttps://www.pharmaradar360.com/article/karnataka-fda-uncovers-farmhouse-drug-scam-with-fake-pfizer-labels-fa113abe91479c41PharmaRadar360en2026-09-21T02:12:57.000ZKarnataka FDA uncovers farmhouse drug scam with fake Pfizer labelshttps://www.pharmaradar360.com/article/abl-bio-s-credibility-in-doubt-as-market-cap-drops-by-10-trillion-won-in-eight-m-6125fa47849c124ePharmaRadar360en2026-09-21T01:56:02.000ZABL Bio's Credibility in Doubt as Market Cap Drops by 10 Trillion Won in Eight Monthshttps://www.pharmaradar360.com/article/cha-biotech-s-us-unit-matica-expands-beyond-cgt-into-protein-cdmo-3e1fa8b19d2893e9PharmaRadar360en2026-09-21T01:55:00.000ZCHA Biotech's US Unit Matica Expands Beyond CGT into Protein CDMOhttps://www.pharmaradar360.com/article/kolon-tissuegene-shifts-to-sole-leadership-as-no-resigns-after-tg-c-setback-chos-78b39badd6d85917PharmaRadar360en2026-09-21T01:38:00.000ZKolon TissueGene shifts to sole leadership as No resigns after TG-C setback - CHOSUNBIZhttps://www.pharmaradar360.com/article/karnataka-fda-cancels-16-drug-licences-after-rs-5-05-crore-spurious-medicine-rac-71f3f5a689bc8cb1PharmaRadar360en2026-09-21T01:25:40.000ZKarnataka FDA cancels 16 drug licences after Rs 5.05 crore spurious medicine racket bustedhttps://www.pharmaradar360.com/article/hansoh-pharmaceutical-says-hs-10374-meets-co-primary-endpoints-in-phase-iii-plaq-c406088c5e696e9dPharmaRadar360en2026-09-21T01:25:00.000ZHansoh Pharmaceutical Says HS-10374 Meets Co-Primary Endpoints In Phase III Plaque Psoriasis Trialhttps://www.pharmaradar360.com/article/from-anti-aging-to-biotech-taiwan-looks-to-take-its-exosomes-global-8b1cffaebe2d4f7aPharmaRadar360en2026-09-21T01:00:00.000ZFrom Anti-Aging to Biotech: Taiwan Looks to Take Its Exosomes Globalhttps://www.pharmaradar360.com/article/antengene-announces-first-patient-dosed-in-pivotal-phase-iii-clinch-3-study-of-a-46d88b9387463d03PharmaRadar360en2026-09-21T00:30:00.000ZAntengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022https://www.pharmaradar360.com/article/hansoh-pharmaceutical-pharma-announces-pivotal-phase-3-clinical-trial-of-hs-1037-5e494e720e07789dPharmaRadar360en2026-09-21T00:24:05.000ZHansoh Pharmaceutical : PHARMA ANNOUNCES PIVOTAL PHASE 3 CLINICAL TRIAL OF HS-10374 IN THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS MET THE CO-PRIMARY ENDPOINTShttps://www.pharmaradar360.com/article/nephrotic-syndrome-clinical-trial-pipeline-gains-momentum-3-3dcb122cc4863365PharmaRadar360en2026-09-21T00:24:02.000ZNephrotic Syndrome Clinical Trial Pipeline Gains Momentum: 3+https://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-20d1e45ad8f41ec4PharmaRadar360en2026-09-21T00:00:00.000ZAstraZeneca filed Form 6-Khttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-348a916341b98888PharmaRadar360en2026-09-21T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-a462bfe6ac69091bPharmaRadar360en2026-09-21T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-0cf31639944043bdPharmaRadar360en2026-09-21T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-d46a9ed1ea676011PharmaRadar360en2026-09-21T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-accd0d14f9e56cc3PharmaRadar360en2026-09-21T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-9ecbe3642bfb6934PharmaRadar360en2026-09-21T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-8ddc7119df671581PharmaRadar360en2026-09-21T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-4cc503afa59e5bd5PharmaRadar360en2026-09-21T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-15a65dc78fc4417cPharmaRadar360en2026-09-21T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-bc6951e16c1b5b7ePharmaRadar360en2026-09-21T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-c3c0b3720fdf14a7PharmaRadar360en2026-09-21T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-fa045d5c5425c89cPharmaRadar360en2026-09-21T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-5f9eb353bd21452cPharmaRadar360en2026-09-21T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-cbd013ceecb6e269PharmaRadar360en2026-09-21T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-f7733853b6214ae0PharmaRadar360en2026-09-21T00:00:00.000ZAgency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Orphan Drugshttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-tem-11a455d22d2f487ePharmaRadar360en2026-09-21T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Temporary Marketing Permit Applicationshttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-sta-3764daf81725a8e8PharmaRadar360en2026-09-21T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; State Petitions for Exemption From Preemptionhttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-pri-46565154b7c80bf6PharmaRadar360en2026-09-21T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Prior Notice of Imported Food Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002https://www.pharmaradar360.com/article/chemistry-manufacturing-and-controls-development-and-readiness-pilot-program-pro-a46738e923f10604PharmaRadar360en2026-09-21T00:00:00.000ZChemistry, Manufacturing, and Controls Development and Readiness Pilot Program; Program Announcementhttps://www.pharmaradar360.com/article/data-intermediaries-and-approaches-to-strengthen-public-health-data-exchange-4fc8495db52da975PharmaRadar360en2026-09-21T00:00:00.000ZData Intermediaries and Approaches To Strengthen Public Health Data Exchangehttps://www.pharmaradar360.com/article/request-for-information-on-electromagnetic-fields-emfs-radiofrequency-rf-radiati-adf4d970aa383e2aPharmaRadar360en2026-09-21T00:00:00.000ZRequest for Information on Electromagnetic Fields (EMFs), Radiofrequency (RF) Radiation, and Wireless Radiation Exposurehttps://www.pharmaradar360.com/article/solicitation-of-nominations-for-membership-on-the-national-vaccine-advisory-comm-7829fc374a16ba21PharmaRadar360en2026-09-21T00:00:00.000ZSolicitation of Nominations for Membership on the National Vaccine Advisory Committeehttps://www.pharmaradar360.com/article/notice-of-supplemental-funding-medicare-rural-hospital-flexibility-program-evalu-34665635a9d20190PharmaRadar360en2026-09-21T00:00:00.000ZNotice of Supplemental Funding, Medicare Rural Hospital Flexibility Program Evaluation Cooperative Agreementhttps://www.pharmaradar360.com/article/notice-of-supplemental-funding-state-offices-of-rural-health-coordination-and-de-f3a019ef42d0893bPharmaRadar360en2026-09-21T00:00:00.000ZNotice of Supplemental Funding, State Offices of Rural Health Coordination and Development Programhttps://www.pharmaradar360.com/article/esther-villanueva-valdes-m-d-decision-and-order-6920fac42a4abfcbPharmaRadar360en2026-09-21T00:00:00.000ZEsther Villanueva Valdes, M.D.; Decision and Orderhttps://www.pharmaradar360.com/article/schedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i-0219f45fb611f4fbPharmaRadar360en2026-09-21T00:00:00.000ZSchedules of Controlled Substances: Placement of Diphenidine in Schedule Ihttps://www.pharmaradar360.com/article/john-ramsay-walters-m-d-decision-and-order-508288de44a083a6PharmaRadar360en2026-09-21T00:00:00.000ZJohn Ramsay Walters, M.D.; Decision and Orderhttps://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-2cd2bb9dfe90d36aPharmaRadar360en2026-09-21T00:00:00.000ZCenter for Scientific Review; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-90b2d8c9d1af74acPharmaRadar360en2026-09-21T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/notice-of-supplemental-funding-rural-quality-improvement-technical-assistance-pr-9960416381329507PharmaRadar360en2026-09-21T00:00:00.000ZNotice of Supplemental Funding, Rural Quality Improvement Technical Assistance Programhttps://www.pharmaradar360.com/article/cleveland-clinic-children-s-expands-newborn-screening-to-identify-virus-that-can-5be78e10f5542c12PharmaRadar360en2026-09-21T00:00:00.000ZCleveland Clinic Children’s Expands Newborn Screening to Identify Virus that Can Lead to Hearing Loss and Developmental Delayshttps://www.pharmaradar360.com/article/effect-of-pharmacist-led-medication-review-on-drug-related-problems-among-outpat-d98465ff90ef3962PharmaRadar360en2026-09-21T00:00:00.000ZEffect of pharmacist-led medication review on drug-related problems among outpatients undergoing elective surgery at a tertiary care hospital: A retrospective studyhttps://www.pharmaradar360.com/article/clinical-and-orthodontic-management-of-impacted-teeth-associated-with-retained-p-4cc1e189c772934dPharmaRadar360en2026-09-21T00:00:00.000ZCLINICAL AND ORTHODONTIC MANAGEMENT OF IMPACTED TEETH ASSOCIATED WITH RETAINED PRIMARY TEETHhttps://www.pharmaradar360.com/article/contemporary-classifications-of-alzheimer-s-disease-a-critical-review-of-clinica-881e2ebbb9a0f093PharmaRadar360en2026-09-21T00:00:00.000ZContemporary Classifications of Alzheimer’s Disease: A Critical Review of Clinical, Biological, Neuropathological, Functional, Phenotypic and Neuroinformational Frameworkshttps://www.pharmaradar360.com/article/comparative-effects-of-myofascial-release-and-bowen-therapy-in-patients-with-tex-0ca1011620b24697PharmaRadar360en2026-09-21T00:00:00.000ZComparative effects of myofascial release and Bowen therapy in patients with text neck syndrome: a randomised clinical trialhttps://www.pharmaradar360.com/article/redefining-post-xenotransplantation-surveillance-leveraging-metagenomic-next-gen-b5529587c7664a12PharmaRadar360en2026-09-21T00:00:00.000ZRedefining post-xenotransplantation surveillance: leveraging metagenomic next-generation sequencing to discriminate true pathogen replication from microchimerism-induced false positiveshttps://www.pharmaradar360.com/article/from-answers-to-agents-what-must-change-before-generative-and-agentic-ai-become-29d767d349ffc4c0PharmaRadar360en2026-09-21T00:00:00.000ZFrom Answers to Agents: What Must Change Before Generative and Agentic AI Become Clinical Infrastructure in Hematologyhttps://www.pharmaradar360.com/article/an-open-label-dose-escalation-trial-of-psilocybin-assisted-therapy-for-bipolar-i-d6af23c5c79be8b0PharmaRadar360en2026-09-21T00:00:00.000ZAn Open-Label, Dose-Escalation Trial of Psilocybin-Assisted Therapy for Bipolar II Depressionhttps://www.pharmaradar360.com/article/nanotechnology-for-drug-delivery-systems-in-colorectal-cancer-recent-development-407dba257167da55PharmaRadar360en2026-09-21T00:00:00.000ZNanotechnology for drug delivery systems in colorectal cancer: Recent developments and future prospectshttps://www.pharmaradar360.com/article/letter-to-the-editor-artificial-intelligence-in-hepatology-when-deep-learning-me-a568d88464097facPharmaRadar360en2026-09-21T00:00:00.000ZLetter to the Editor: Artificial intelligence in hepatology - when deep learning meets drug-induced liver injuryhttps://www.pharmaradar360.com/article/polyethylene-glycol-based-bowel-preparation-and-gut-dysbiosis-clinical-implicati-0b34416aee8a965bPharmaRadar360en2026-09-21T00:00:00.000ZPolyethylene glycol-based bowel preparation and gut dysbiosis: Clinical implications beyond colon cleansinghttps://www.pharmaradar360.com/article/b3c94bebd28f7b8aPharmaRadar360en2026-09-21T00:00:00.000ZСравнительный анализ воспалительной реакции после имплантации биологических и синтетических сосудистых протезов: многоцентровое рандомизированное клиническое исследованиеhttps://www.pharmaradar360.com/article/a-longitudinal-analysis-of-the-clinical-practice-of-ketamine-assisted-psychother-6ab9b95624cbf138PharmaRadar360en2026-09-21T00:00:00.000ZA longitudinal analysis of the clinical practice of ketamine assisted psychotherapy with adolescents and young adultshttps://www.pharmaradar360.com/article/precision-cut-tumor-slices-a-biomimetic-tool-for-accelerating-oncological-develo-7226c7cb1b69ee04PharmaRadar360en2026-09-21T00:00:00.000ZPrecision-cut tumor slices: a biomimetic tool for accelerating oncological development from basic research to clinical translationhttps://www.pharmaradar360.com/article/evaluating-a-large-language-model-chatgpt-5-for-detecting-potential-drug-drug-in-816f2974050e0720PharmaRadar360en2026-09-21T00:00:00.000ZEvaluating a large language model (ChatGPT-5) for detecting potential drug–drug interactions in intensive care: a cross-sectional comparative study with a clinical decision support systemhttps://www.pharmaradar360.com/article/explainable-ai-based-prognostication-of-patients-with-resectable-colorectal-live-2fbabdacdf9df95dPharmaRadar360en2026-09-21T00:00:00.000ZExplainable AI–based prognostication of patients with resectable colorectal liver metastases using preoperative clinical parameters: is it comparable to traditional clinical scoring systems?https://www.pharmaradar360.com/article/clinical-outcomes-of-individualized-surgical-pathways-in-elderly-patients-with-s-8be373a0ada7c9acPharmaRadar360en2026-09-21T00:00:00.000ZClinical outcomes of individualized surgical pathways in elderly patients with spinal tuberculosis: a retrospective cohort study in eastern Chinahttps://www.pharmaradar360.com/article/cholesterol-in-hematological-malignancies-metabolism-mechanisms-and-clinical-imp-9a30fa29c2722f2ePharmaRadar360en2026-09-21T00:00:00.000ZCholesterol in hematological malignancies: metabolism, mechanisms, and clinical implicationshttps://www.pharmaradar360.com/article/radiomics-and-deep-learning-for-immune-checkpoint-inhibitor-outcomes-imaging-der-c24c9e0431952223PharmaRadar360en2026-09-21T00:00:00.000ZRadiomics and deep learning for immune checkpoint inhibitor outcomes: imaging-derived immune phenotyping and clinical translation across solid tumorshttps://www.pharmaradar360.com/article/editorial-hypertension-and-endocrine-pathways-molecular-and-clinical-perspective-f45527b617e638a0PharmaRadar360en2026-09-21T00:00:00.000ZEditorial: Hypertension and endocrine pathways: molecular and clinical perspectiveshttps://www.pharmaradar360.com/article/association-of-metabolic-indices-with-in-stent-restenosis-and-its-angiographic-s-e1466792d8c505f7PharmaRadar360en2026-09-21T00:00:00.000ZAssociation of metabolic indices with in-stent restenosis and its angiographic severity after drug-eluting stent implantation: a case-control studyhttps://www.pharmaradar360.com/article/artificial-intelligence-for-alcohol-opioid-and-cannabis-use-disorders-screening-af0d522dc83a2f40PharmaRadar360en2026-09-21T00:00:00.000ZArtificial intelligence for alcohol, opioid, and cannabis use disorders screening and management: a narrative review of barriers and facilitators to clinical implementationhttps://www.pharmaradar360.com/article/clinical-outcomes-of-endovascular-stenting-versus-bypass-surgery-for-aortoiliac-c8a13ad848e43792PharmaRadar360en2026-09-21T00:00:00.000ZClinical outcomes of endovascular stenting versus bypass surgery for aortoiliac occlusive disease: a single-center retrospective cohort studyhttps://www.pharmaradar360.com/article/experimental-data-analysis-and-improved-cytochrome-p450-site-of-metabolism-predi-c9f109a994421ccaPharmaRadar360en2026-09-21T00:00:00.000ZExperimental Data Analysis and Improved Cytochrome P450 Site-of-Metabolism Prediction for Drug Discoveryhttps://www.pharmaradar360.com/article/clinical-evaluation-of-surgical-management-of-humeral-fractures-in-dogs-630477cc2610da7aPharmaRadar360en2026-09-21T00:00:00.000ZClinical Evaluation of Surgical Management of Humeral Fractures in Dogshttps://www.pharmaradar360.com/article/clinical-prediction-with-time-varying-predictors-in-pediatric-hospital-medicine-e1b6797d232c89ebPharmaRadar360en2026-09-21T00:00:00.000ZClinical Prediction With Time-Varying Predictors in Pediatric Hospital Medicinehttps://www.pharmaradar360.com/article/72120-role-of-cross-coupling-reactions-in-drug-discovery-and-development-c3d94fd4f2f85350PharmaRadar360en2026-09-21T00:00:00.000Z72120 Role of cross-coupling reactions in drug discovery and developmenthttps://www.pharmaradar360.com/article/early-clinical-and-laboratory-findings-associated-with-mortality-during-continuo-9407e7b095fca8cfPharmaRadar360en2026-09-21T00:00:00.000ZEarly clinical and laboratory findings associated with mortality during continuous renal replacement therapy in neonateshttps://www.pharmaradar360.com/article/association-between-age-and-outcomes-of-evidence-based-feeding-protocol-versus-u-55c081db85ef4e3dPharmaRadar360en2026-09-21T00:00:00.000ZAssociation between age and outcomes of evidence-based feeding protocol versus usual care in critically ill patients: secondary analysis of a multicenter cluster-randomised controlled trialhttps://www.pharmaradar360.com/article/a-randomized-controlled-trial-of-the-unified-treatment-for-emotion-regulation-an-95ba566aa1d0d048PharmaRadar360en2026-09-21T00:00:00.000ZA randomized controlled trial of the unified treatment for emotion regulation and body image dissatisfaction in adolescents with subclinical eating-disorder symptomshttps://www.pharmaradar360.com/article/correction-to-environmental-burden-of-the-neuro-conda-trial-b843a9e61763332fPharmaRadar360en2026-09-21T00:00:00.000ZCorrection to: Environmental burden of the neuro-conda trialhttps://www.pharmaradar360.com/article/two-liberations-two-physiological-targets-implications-of-the-x-copd-trial-d4756dae96dd95bfPharmaRadar360en2026-09-21T00:00:00.000ZTwo liberations, two physiological targets: implications of the X-COPD trialhttps://www.pharmaradar360.com/article/clinical-and-genetic-spectrum-of-dual-rare-genetic-diseases-revealed-by-whole-ex-c11cb01b29dfbeacPharmaRadar360en2026-09-21T00:00:00.000ZClinical and genetic spectrum of dual rare genetic diseases revealed by whole-exome sequencing in 14 pediatric patientshttps://www.pharmaradar360.com/article/comparing-the-effectiveness-of-sexual-education-lactofem-probiotic-supplementati-6de2093c73f923aePharmaRadar360en2026-09-21T00:00:00.000ZComparing the effectiveness of sexual education, Lactofem probiotic supplementation, and a combined approach on sexual function, sexual satisfaction, and quality of life in postmenopausal women: a single-blind randomized clinical trialhttps://www.pharmaradar360.com/article/effect-of-tricalcium-phosphate-grafting-on-implant-stability-and-peri-implant-ra-6c4647c34f739ce5PharmaRadar360en2026-09-21T00:00:00.000ZEffect of β-tricalcium phosphate grafting on implant stability and peri-implant radiodensity following immediate implant placement in sites with jumping gaps exceeding 2 mm: a randomized controlled trialhttps://www.pharmaradar360.com/article/early-clinical-outcomes-and-learning-curve-study-of-robot-assisted-precision-ost-e633bc562db9c390PharmaRadar360en2026-09-21T00:00:00.000ZEarly clinical outcomes and learning curve study of robot-assisted precision osteotomy in total knee arthroplasty in the context of enhanced recovery after surgeryhttps://www.pharmaradar360.com/article/reproductive-health-factors-associated-with-clinical-breast-examination-uptake-a-1fb1bdc964c44801PharmaRadar360en2026-09-21T00:00:00.000ZReproductive health factors associated with clinical breast examination uptake among Ghanaian womenhttps://www.pharmaradar360.com/article/is-it-possible-to-implement-the-dialog-routine-outcome-monitoring-system-in-a-ps-154907870f8fd3d8PharmaRadar360en2026-09-21T00:00:00.000ZIs it possible to implement the DIALOG+ routine outcome monitoring system in a psychiatric rehabilitation inpatient setting? A mixed methods feasibility trial in the UK National Health Servicehttps://www.pharmaradar360.com/article/controlled-evaluation-of-architectural-classifier-and-training-refinements-in-mo-9b6b5ebafa237da4PharmaRadar360en2026-09-21T00:00:00.000ZControlled evaluation of architectural, classifier, and training refinements in MolTrans-based drug-target interaction predictionhttps://www.pharmaradar360.com/article/clinical-case-abstracts-presented-at-the-2026-vascular-scientific-sessions-of-th-17356abbdb3b6348PharmaRadar360en2026-09-21T00:00:00.000ZClinical Case Abstracts Presented at the 2026 Vascular Scientific Sessions of the Society for Vascular Medicinehttps://www.pharmaradar360.com/article/a-case-of-acute-mania-and-rhabdomyolysis-associated-with-long-term-daily-psilocy-5e9ff14ba01f20d2PharmaRadar360en2026-09-21T00:00:00.000ZA Case of Acute Mania and Rhabdomyolysis Associated With Long-Term, Daily Psilocybin Usehttps://www.pharmaradar360.com/article/successful-linezolid-based-treatment-of-nocardia-otitidiscaviarum-pneumonia-in-a-75522611e0215260PharmaRadar360en2026-09-21T00:00:00.000ZSuccessful Linezolid-Based Treatment of Nocardia otitidiscaviarum Pneumonia in an Immunocompetent Patienthttps://www.pharmaradar360.com/article/correction-to-kdigo-2026-clinical-practice-guideline-for-anemia-in-chronic-kidne-a000d38d61280e8dPharmaRadar360en2026-09-21T00:00:00.000ZCorrection to: KDIGO 2026 Clinical Practice Guideline for Anemia in Chronic Kidney Disease (CKD): a commentary from the European Renal Best Practice (ERBP)https://www.pharmaradar360.com/article/plga-nanoparticles-co-loaded-with-resveratrol-and-doxycycline-for-dual-action-pe-939ca4ac398814e2PharmaRadar360en2026-09-21T00:00:00.000ZPLGA nanoparticles co-loaded with resveratrol and doxycycline for dual-action periodontal therapy: <i>in vitro</i> and <i>in vivo</i> evaluationhttps://www.pharmaradar360.com/article/history-of-instruments-and-technology-in-the-clinical-neurosciences-1-a-new-colu-20dd0b4b14d65df6PharmaRadar360en2026-09-21T00:00:00.000ZHistory of instruments and technology in the clinical neurosciences: 1. A new column for <i>Journal of the History of the Neurosciences</i>https://www.pharmaradar360.com/article/early-renal-replacement-therapy-and-short-term-mortality-in-higher-risk-kdigo-st-24cf7609b60ad216PharmaRadar360en2026-09-21T00:00:00.000ZEarly renal replacement therapy and short-term mortality in higher-risk KDIGO stage 2 sepsis-associated acute kidney injury with sustained oliguria: a target trial emulationhttps://www.pharmaradar360.com/article/features-and-a-specific-pattern-of-cerebral-perfusion-in-patients-with-lewy-body-355df3a541cce01ePharmaRadar360en2026-09-21T00:00:00.000ZFeatures and a specific pattern of cerebral perfusion in patients with Lewy body dementia: Diagnostic ability and clinical correlationshttps://www.pharmaradar360.com/article/nanomaterial-driven-innovation-integrating-catalytic-quinoline-synthesis-and-ant-8cf496cf1a6deeeePharmaRadar360en2026-09-21T00:00:00.000ZNanomaterial-driven innovation: integrating catalytic quinoline synthesis and anti-allergy drug design using Ta-doped NiO/ZIF-8 nanorod compositeshttps://www.pharmaradar360.com/article/the-frontal-qrs-t-angle-and-cardiovascular-disease-a-narrative-review-of-electro-cbbb96a76080672aPharmaRadar360en2026-09-21T00:00:00.000ZThe Frontal QRS-T Angle and Cardiovascular Disease: A Narrative Review of Electrophysiological Basis, Measurement, and Clinical Utilityhttps://www.pharmaradar360.com/article/omental-infarction-mimicking-acute-appendicitis-a-case-series-and-systematic-rev-abd897ddb9f816d8PharmaRadar360en2026-09-21T00:00:00.000ZOmental Infarction Mimicking Acute Appendicitis: A Case Series and Systematic Review of Clinical, Radiological, and Management Outcomeshttps://www.pharmaradar360.com/article/bergen-barbers-a-student-run-haircut-and-grooming-service-to-enhance-empathy-cli-2d783afe88dd1ff0PharmaRadar360en2026-09-21T00:00:00.000ZBergen Barbers: A Student-Run Haircut and Grooming Service to Enhance Empathy, Clinical Comfort, and Patient-Centered Skills in Medical Educationhttps://www.pharmaradar360.com/article/technology-profiles-in-fda-approved-new-molecular-entities-2013-2024-a-latent-cl-14b45ca875a5e683PharmaRadar360en2026-09-21T00:00:00.000ZTechnology profiles in FDA-approved new molecular entities, 2013–2024: a latent class analysishttps://www.pharmaradar360.com/article/using-pre-study-patient-interviews-to-refine-electronic-patient-reported-outcome-180e87a5a4637f62PharmaRadar360en2026-09-21T00:00:00.000ZUsing Pre-Study Patient Interviews to Refine Electronic Patient-Reported Outcomes in Clinical Research of Ustekinumab Induction for Ulcerative Colitis (SIRIUS Study)https://www.pharmaradar360.com/article/qualitatssicherung-in-der-notfallmedizin-klinische-routinedaten-zur-kontinuierli-9ef90c7e92ec7796PharmaRadar360en2026-09-21T00:00:00.000ZQualitätssicherung in der Notfallmedizin – klinische Routinedaten zur kontinuierlichen Verbesserung der Versorgunghttps://www.pharmaradar360.com/article/vagus-nerve-stimulation-in-rheumatic-diseases-linking-autonomic-nervous-system-r-fc25d41224e56bfaPharmaRadar360en2026-09-21T00:00:00.000ZVagus nerve stimulation in rheumatic diseases: linking autonomic nervous system regulation, inflammation, and clinical outcomeshttps://www.pharmaradar360.com/article/masking-effect-in-the-spanish-spontaneous-reporting-database-fedra-ed8e769df5841923PharmaRadar360en2026-09-21T00:00:00.000ZMasking effect in the Spanish spontaneous reporting database FEDRAhttps://www.pharmaradar360.com/article/a-multicenter-randomized-double-blinded-placebo-controlled-phase-2-trial-to-eval-b630ccd85cfbb5faPharmaRadar360en2026-09-21T00:00:00.000ZA multicenter randomized, double-blinded placebo-controlled phase 2 trial to evaluate safety and efficacy of ilofotase alfa in patients at risk for kidney injury following open heart surgeryhttps://www.pharmaradar360.com/article/clinical-effectiveness-of-sialendoscopy-in-radioactive-iodine-induced-sialadenit-0b3e7d49e37b1880PharmaRadar360en2026-09-21T00:00:00.000ZClinical Effectiveness of Sialendoscopy in Radioactive Iodine‐induced Sialadenitis: A Systematic Review and Meta‐analysishttps://www.pharmaradar360.com/article/osteomyelitis-epidemiology-classification-pathophysiology-clinical-features-diag-d34e3ed15fd784bdPharmaRadar360en2026-09-21T00:00:00.000ZOsteomyelitis: Epidemiology, Classification, Pathophysiology, Clinical Features, Diagnosis, and Managementhttps://www.pharmaradar360.com/article/drug-free-remission-in-early-peripheral-spondyloarthritis-including-psoriatic-ar-6c81cca77d0e9b70PharmaRadar360en2026-09-21T00:00:00.000ZDrug‐Free Remission in Early Peripheral Spondyloarthritis, including Psoriatic Arthritis: 10‐year follow‐up from the CRESPA trialhttps://www.pharmaradar360.com/article/treatment-approaches-to-macrophage-activation-syndrome-in-real-life-and-prioriti-102fe79d4968ac65PharmaRadar360en2026-09-21T00:00:00.000ZTreatment approaches to macrophage activation syndrome in real life and priorities for future research: results from the international METAPHOR projecthttps://www.pharmaradar360.com/article/nct07831876-a-study-of-ear-nerve-stimulation-to-treat-eye-inflammation-e4573db9274a7699PharmaRadar360en2026-09-21T00:00:00.000ZNCT07831876: A Study of Ear Nerve Stimulation to Treat Eye Inflammationhttps://www.pharmaradar360.com/article/nct07831837-evaluation-and-implementation-of-digital-health-ecosystem-in-academi-fdcdcc46b03062f5PharmaRadar360en2026-09-21T00:00:00.000ZNCT07831837: Evaluation and Implementation of Digital Health Ecosystem in Academic Health Centerhttps://www.pharmaradar360.com/article/nct07831304-randomized-prospective-trial-on-the-cost-effectiveness-of-photon-cou-447db65ba37a6fccPharmaRadar360en2026-09-21T00:00:00.000ZNCT07831304: Randomized Prospective Trial on the Cost-Effectiveness of Photon-Counting CT Versus Energy-Integrating Detector CT in Suspected Chronic Coronary Syndromehttps://www.pharmaradar360.com/article/nct07831265-a-prospective-randomized-controlled-trial-of-dynamic-fixation-for-co-55d0b71452ea5131PharmaRadar360en2026-09-21T00:00:00.000ZNCT07831265: A Prospective Randomized Controlled Trial of Dynamic Fixation for Complex Ankle Fractures With Syndesmotic Diastasis.https://www.pharmaradar360.com/article/nct07831226-safety-and-immunogenicity-of-the-recombinant-malaria-vaccines-in-hea-2bcd3e04222cd35aPharmaRadar360en2026-09-21T00:00:00.000ZNCT07831226: Safety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-59 Yearshttps://www.pharmaradar360.com/article/nct07831161-safety-and-efficacy-of-autologous-natural-killer-cell-therapy-chank-7684ab7dca353214PharmaRadar360en2026-09-21T00:00:00.000ZNCT07831161: Safety and Efficacy of Autologous Natural Killer Cell Therapy (CHANK-101) in Patients With Recurrent Glioblastomahttps://www.pharmaradar360.com/article/nct07830836-physiotherapy-and-osteopathic-treatment-for-pain-in-the-cervical-and-20384e7f0eeba594PharmaRadar360en2026-09-21T00:00:00.000ZNCT07830836: Physiotherapy and Osteopathic Treatment for Pain in the Cervical and Lumbar Spine and Temporomandibular Jointshttps://www.pharmaradar360.com/article/nct07830355-immunotherapy-plus-anlotinib-after-surgery-for-esophageal-squamous-c-5dd9b5e748bcb337PharmaRadar360en2026-09-21T00:00:00.000ZNCT07830355: Immunotherapy Plus Anlotinib After Surgery for Esophageal Squamous Cell Cancer With Residual Tumor and Positive Lymph Nodeshttps://www.pharmaradar360.com/article/nct07830004-plasmatic-biomarkers-associated-with-short-term-luspatercept-treatme-9f16e1451340d3d9PharmaRadar360en2026-09-21T00:00:00.000ZNCT07830004: Plasmatic Biomarkers Associated With Short-term Luspatercept Treatment of Lower Risk Myelodysplastic Syndromes (MDS) Patientshttps://www.pharmaradar360.com/article/nct07829978-impact-of-diagnostic-and-therapeutic-upper-and-lower-gastrointestina-2f65ffa869894003PharmaRadar360en2026-09-21T00:00:00.000ZNCT07829978: Impact of Diagnostic and Therapeutic Upper and Lower Gastrointestinal Endoscopic Management on Critically Ill Patients in Fayoum University Hospitalshttps://www.pharmaradar360.com/article/nct07829809-serum-adropin-as-an-indicator-of-endothelial-dysfunction-and-disease-595c2cf7ea30a7afPharmaRadar360en2026-09-21T00:00:00.000ZNCT07829809: Serum Adropin as an Indicator of Endothelial Dysfunction and Disease Severity in Obstructive Sleep Apnea in Obese Patientshttps://www.pharmaradar360.com/article/nct07819747-resources-and-education-for-addressing-chronic-health-reach-5c8914fdbf6ad407PharmaRadar360en2026-09-21T00:00:00.000ZNCT07819747: Resources and Education for Addressing Chronic Health (REACH)https://www.pharmaradar360.com/article/nct07796373-nemtabrutinib-for-chronic-lymphocytic-leukemia-cll-small-lymphocytic-38cf1b9c433f4464PharmaRadar360en2026-09-21T00:00:00.000ZNCT07796373: Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitorhttps://www.pharmaradar360.com/article/nct07793383-adaptive-decision-support-for-addiction-treatment-adapt-serial-rando-c8142426532c5676PharmaRadar360en2026-09-21T00:00:00.000ZNCT07793383: Adaptive Decision Support for Addiction Treatment (ADAPT) Serial Randomized Testing for Usability, Round 3https://www.pharmaradar360.com/article/nct07744152-a-study-to-test-how-well-different-doses-of-bi-3822971-are-tolerated-89d0e68398e8cbf3PharmaRadar360en2026-09-21T00:00:00.000ZNCT07744152: A Study to Test How Well Different Doses of BI 3822971 Are Tolerated by People With Advanced Cancer (Solid Tumours)https://www.pharmaradar360.com/article/nct07705880-a-novel-clinical-decision-support-tool-to-predict-submucosal-invasiv-73c69ebdf5d8163ePharmaRadar360en2026-09-21T00:00:00.000ZNCT07705880: A Novel Clinical Decision Support Tool to Predict Submucosal Invasive Cancer Within Large Non-Pedunculated Colorectal Polypshttps://www.pharmaradar360.com/article/nct07693751-a-study-to-assess-safety-and-efficacy-of-sot109-in-patients-with-adv-14346cd0d70e71ffPharmaRadar360en2026-09-21T00:00:00.000ZNCT07693751: A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancerhttps://www.pharmaradar360.com/article/nct07616206-cadisegliatin-as-adjunctive-therapy-to-insulin-in-participants-with-5af473b6b56cac59PharmaRadar360en2026-09-21T00:00:00.000ZNCT07616206: Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systemshttps://www.pharmaradar360.com/article/nct07577661-combination-upper-airway-electrical-and-pharmacological-stimulation-898bbd982429e10aPharmaRadar360en2026-09-21T00:00:00.000ZNCT07577661: Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apneahttps://www.pharmaradar360.com/article/nct07572240-a-clinical-trial-to-assess-the-effect-of-ap-brain-collagen-peptides-c72f6d5ff4530877PharmaRadar360en2026-09-21T00:00:00.000ZNCT07572240: A Clinical Trial to Assess the Effect of AP-Brain Collagen Peptides on the Improvement of Attention, Focus, and Memory in Stressed But Otherwise Healthy Individualshttps://www.pharmaradar360.com/article/nct07495943-effects-of-2-aticyto-complex-and-d-ribose-on-pain-and-clinical-cours-101475d12f61e662PharmaRadar360en2026-09-21T00:00:00.000ZNCT07495943: Effects of 2-Aticyto Complex and D-Ribose on Pain and Clinical Course in Patients With Fibromyalgiahttps://www.pharmaradar360.com/article/nct07266831-a-clinical-study-of-islatravir-and-ulonivirine-for-people-with-hiv-1-eee6bd7200b16053PharmaRadar360en2026-09-21T00:00:00.000ZNCT07266831: A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)https://www.pharmaradar360.com/article/nct07262346-the-phase-id-clinical-trial-of-hydronidone-capsules-b492d9ed0ab0ced8PharmaRadar360en2026-09-21T00:00:00.000ZNCT07262346: The Phase Ⅰd Clinical Trial of Hydronidone Capsuleshttps://www.pharmaradar360.com/article/nct07248839-a-study-to-assess-the-drug-levels-and-safety-of-bms-986435-in-partic-6bcf7865fc797437PharmaRadar360en2026-09-21T00:00:00.000ZNCT07248839: A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairmenthttps://www.pharmaradar360.com/article/nct07237217-guided-group-telehealth-to-deliver-evidence-based-therapeutic-care-t-429f74fb322a7209PharmaRadar360en2026-09-21T00:00:00.000ZNCT07237217: Guided Group Telehealth to Deliver Evidence-based Therapeutic Care to Black College Studentshttps://www.pharmaradar360.com/article/nct07232030-barostim-enabled-neurohormonal-intervention-for-improving-treatment-b8fbe5404be54fc1PharmaRadar360en2026-09-21T00:00:00.000ZNCT07232030: Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failurehttps://www.pharmaradar360.com/article/nct07211633-a-study-to-evaluate-the-pharmacokinetics-pharmacodynamics-safety-rad-9469e73414b30703PharmaRadar360en2026-09-21T00:00:00.000ZNCT07211633: A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)https://www.pharmaradar360.com/article/nct07194044-metastatic-ewing-s-trial-testing-schedule-enhancement-to-improve-out-15ff028aa39b88b0PharmaRadar360en2026-09-21T00:00:00.000ZNCT07194044: Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomeshttps://www.pharmaradar360.com/article/nct07161037-phase-2a-study-of-vx-407-in-participants-with-adpkd-who-have-a-subse-5b834aa1cbecaacdPharmaRadar360en2026-09-21T00:00:00.000ZNCT07161037: Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)https://www.pharmaradar360.com/article/nct07111065-fast-for-dm-fatty-acid-supplementation-trial-fast-for-dermatomyositi-ed2b3f59cab40468PharmaRadar360en2026-09-21T00:00:00.000ZNCT07111065: FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)https://www.pharmaradar360.com/article/nct06991738-177lu-dota-eb-tate-in-adult-patients-with-metastatic-radioactive-iod-8bb88397e09523fdPharmaRadar360en2026-09-21T00:00:00.000ZNCT06991738: 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancerhttps://www.pharmaradar360.com/article/nct06980077-ivonescimab-for-the-treatment-of-thymic-cancer-e1c7cd84dfd11be5PharmaRadar360en2026-09-21T00:00:00.000ZNCT06980077: Ivonescimab for the Treatment of Thymic Cancerhttps://www.pharmaradar360.com/article/nct06948110-deciphering-the-genetic-architecture-of-autoimmune-diseases-353665cab37b522aPharmaRadar360en2026-09-21T00:00:00.000ZNCT06948110: Deciphering the Genetic Architecture of Autoimmune Diseaseshttps://www.pharmaradar360.com/article/nct06904066-autologous-t-cells-transduced-with-retroviral-vectors-expressing-tcr-8a1bed717e911091PharmaRadar360en2026-09-21T00:00:00.000ZNCT06904066: Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancieshttps://www.pharmaradar360.com/article/nct06876142-combination-therapy-mirdametinib-and-sirolimus-for-ras-mutated-relap-84e0260330113171PharmaRadar360en2026-09-21T00:00:00.000ZNCT06876142: Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myelomahttps://www.pharmaradar360.com/article/nct06843213-teaching-health-resilience-in-a-hospital-setting-a-peer-led-interven-728fcecdf8ae1e52PharmaRadar360en2026-09-21T00:00:00.000ZNCT06843213: Teaching Health Resilience in a Hospital Setting: A Peer-led Interventionhttps://www.pharmaradar360.com/article/nct06840262-target-muscle-re-innervation-and-regenerative-peripheral-nerve-inter-108eb92d9877d646PharmaRadar360en2026-09-21T00:00:00.000ZNCT06840262: Target Muscle Re-innervation and Regenerative Peripheral Nerve Interfaces Alone and in Combination for the Treatment of Residual and Phantom Limb Pain in Cancer Patients Who Have Received an Amputationhttps://www.pharmaradar360.com/article/nct06732401-testing-the-addition-of-azd6738-ceralasertib-to-immunotherapy-to-inc-c8470b82beaaa53ePharmaRadar360en2026-09-21T00:00:00.000ZNCT06732401: Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancerhttps://www.pharmaradar360.com/article/nct06549595-a-study-of-surovatamig-azd0486-plus-rituximab-in-previously-untreate-07a6329d0563476dPharmaRadar360en2026-09-21T00:00:00.000ZNCT06549595: A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patientshttps://www.pharmaradar360.com/article/nct06473532-text4hf-a-randomized-controlled-trial-of-a-tailored-text-messaging-i-ff5a3fb7b713be45PharmaRadar360en2026-09-21T00:00:00.000ZNCT06473532: TEXT4HF: A Randomized Controlled Trial of a Tailored Text Messaging Intervention to Improve Self-Care in Older Adult Patients With Heart Failurehttps://www.pharmaradar360.com/article/nct06375915-precision-medicine-in-patients-with-unresectable-cholangiocarcinoma-1a7cbd79e9ebb164PharmaRadar360en2026-09-21T00:00:00.000ZNCT06375915: Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapyhttps://www.pharmaradar360.com/article/nct06368388-establishing-personalized-phage-therapy-and-its-comparative-cost-in-0a7ef44acf69cabePharmaRadar360en2026-09-21T00:00:00.000ZNCT06368388: Establishing Personalized Phage Therapy and Its Comparative Cost in Difficult-to-treat Infections (EPHICACI)https://www.pharmaradar360.com/article/nct06337318-comparing-rituximab-and-mosunetuzumab-drug-treatments-for-people-wit-f9c0f74dff068b0ePharmaRadar360en2026-09-21T00:00:00.000ZNCT06337318: Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphomahttps://www.pharmaradar360.com/article/nct06326047-a-research-study-comparing-how-well-different-doses-of-the-medicine-f6ec57cf0b2fe58dPharmaRadar360en2026-09-21T00:00:00.000ZNCT06326047: A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabeteshttps://www.pharmaradar360.com/article/nct06210373-assessment-of-efficacy-and-safety-of-the-use-of-two-eye-gel-products-0073804eb26c0a5cPharmaRadar360en2026-09-21T00:00:00.000ZNCT06210373: Assessment of Efficacy and Safety of the Use of Two Eye Gel Products Containing 5% Dexpanthenol in Patients With Moderate to Severe Dry Eye Syndromehttps://www.pharmaradar360.com/article/nct06149793-sglt2-inhibitor-therapy-in-cystic-fibrosis-related-diabetes-7fdca58a4e7cc302PharmaRadar360en2026-09-21T00:00:00.000ZNCT06149793: SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabeteshttps://www.pharmaradar360.com/article/nct06120244-establishment-of-biobank-of-nasal-epithelium-samples-from-healthy-vo-147d3c56bb9915e2PharmaRadar360en2026-09-21T00:00:00.000ZNCT06120244: Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteershttps://www.pharmaradar360.com/article/nct06038032-improving-health-behaviours-for-life-after-endometrial-cancer-trial-4118e5d6f2fdb4fePharmaRadar360en2026-09-21T00:00:00.000ZNCT06038032: ImpRoving hEalth behaviourS for LIfe After ENdometrial CancEr Trialhttps://www.pharmaradar360.com/article/nct06005740-a-phase-1-first-in-human-study-of-torl-4-500-in-patients-with-advanc-c709207ba78bf3a0PharmaRadar360en2026-09-21T00:00:00.000ZNCT06005740: A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancerhttps://www.pharmaradar360.com/article/nct05842330-benefits-of-adhd-treatment-in-detained-people-06046ff851a60e9fPharmaRadar360en2026-09-21T00:00:00.000ZNCT05842330: Benefits of ADHD Treatment in Detained Peoplehttps://www.pharmaradar360.com/article/nct05383274-optilume-post-approval-clinical-evaluation-of-andrology-parameters-bc64816ab9b77eb5PharmaRadar360en2026-09-21T00:00:00.000ZNCT05383274: Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMetershttps://www.pharmaradar360.com/article/nct05041309-long-term-follow-up-study-after-gene-modified-cell-treatment-in-kite-de88c2de50133c8aPharmaRadar360en2026-09-21T00:00:00.000ZNCT05041309: Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studieshttps://www.pharmaradar360.com/article/nct04984005-the-interaction-and-regulation-mechanism-of-different-exercise-patte-093e891995b9f987PharmaRadar360en2026-09-21T00:00:00.000ZNCT04984005: The Interaction and Regulation Mechanism of Different Exercise Patterns With Metabolic Syndrome and Related Metabolic Diseaseshttps://www.pharmaradar360.com/article/nct04512209-characterization-of-biophysical-stromal-properties-in-human-cancer-t-4b671ba1b3860be3PharmaRadar360en2026-09-21T00:00:00.000ZNCT04512209: Characterization of Biophysical Stromal Properties in Human Cancer: Towards Personalized Computational Oncologyhttps://www.pharmaradar360.com/article/nct04359732-assessment-of-response-to-ncrt-for-gej-cancer-using-a-fully-integrat-8c8a048767bc00f6PharmaRadar360en2026-09-21T00:00:00.000ZNCT04359732: Assessment of Response to nCRT for GEJ Cancer Using a Fully Integrated PET/MRIhttps://www.pharmaradar360.com/article/nct04018092-the-revitalize-study-in-older-adults-at-risk-for-alzheimer-s-disease-dbe5d764e71a0caaPharmaRadar360en2026-09-21T00:00:00.000ZNCT04018092: The Revitalize Study in Older Adults at Risk for Alzheimer's Diseasehttps://www.pharmaradar360.com/article/nct03226704-leukapheresis-for-car-or-adoptive-cell-therapy-manufacturing-8859eb3be74c76caPharmaRadar360en2026-09-21T00:00:00.000ZNCT03226704: Leukapheresis for CAR or Adoptive Cell Therapy Manufacturinghttps://www.pharmaradar360.com/article/nct03223103-safety-and-immunogenicity-of-personalized-genomic-vaccine-and-tumor-f248e56d06f14a0aPharmaRadar360en2026-09-21T00:00:00.000ZNCT03223103: Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastomahttps://www.pharmaradar360.com/article/nct02003222-combination-chemotherapy-with-or-without-blinatumomab-in-treating-pa-489f33c4c086296dPharmaRadar360en2026-09-21T00:00:00.000ZNCT02003222: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemiahttps://www.pharmaradar360.com/article/nct01496625-national-eye-institute-biorepository-for-retinal-diseases-99078260bf2b6307PharmaRadar360en2026-09-21T00:00:00.000ZNCT01496625: National Eye Institute Biorepository for Retinal Diseaseshttps://www.pharmaradar360.com/article/paradigm-biopharmaceuticals-halts-trading-ahead-of-phase-3-trial-update-aa25a9abde83efd3PharmaRadar360en2026-09-20T23:48:44.000ZParadigm Biopharmaceuticals Halts Trading Ahead of Phase 3 Trial Updatehttps://www.pharmaradar360.com/article/click-estock-aribio-holdings-set-to-announce-ar1001-phase-3-results-rapid-commer-cc4b1439181b24d5PharmaRadar360en2026-09-20T23:37:10.000Z[Click eStock] "Aribio Holdings Set to Announce AR1001 Phase 3 Results... Rapid Commercialization Expected"https://www.pharmaradar360.com/article/expert-team-to-drive-improvements-in-cancer-care-417d32b858766792PharmaRadar360en2026-09-20T23:01:01.000ZExpert team to drive improvements in cancer carehttps://www.pharmaradar360.com/article/market-movers-rx-west-pharmaceutical-services-leads-gainers-d11ab73a9d464311PharmaRadar360en2026-09-20T22:53:23.000ZMarket Movers RX: West Pharmaceutical Services Leads Gainershttps://www.pharmaradar360.com/article/sls-ibrx-eye-green-month-as-biotech-etf-gains-steam-analyst-sees-continued-oppor-6a1aa66cf3396998PharmaRadar360en2026-09-20T22:25:25.000ZSLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees ‘Continued Opportunities’ In Immuno-Oncologyhttps://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32PharmaRadar360en2026-09-20T22:20:20.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/battles-in-u-s-war-on-cancer-being-waged-at-white-plains-hospital-d5ac453bc8b5b463PharmaRadar360en2026-09-20T21:37:30.000ZBattles in U.S. war on cancer being waged at White Plains Hospitalhttps://www.pharmaradar360.com/article/abbvie-s-bet-on-biology-why-one-modality-is-never-enough-in-lung-cancer-22ddcff0c7b1d6dePharmaRadar360en2026-09-20T19:01:58.000ZAbbVie’s Bet on Biology: Why One Modality Is Never Enough in Lung Cancerhttps://www.pharmaradar360.com/article/when-the-trial-fails-was-it-the-drug-or-the-design-7d9fc4711d67aecdPharmaRadar360en2026-09-20T19:01:58.000ZWhen the Trial Fails, Was It the Drug or the Design?https://www.pharmaradar360.com/article/liminal-biosciences-stock-remains-without-fresh-data-in-latest-search-window-e69750d05b62c05dPharmaRadar360en2026-09-20T18:36:48.000ZLiminal Biosciences stock remains without fresh data in latest search windowhttps://www.pharmaradar360.com/article/igm-biosciences-stock-trades-quietly-amid-lack-of-fresh-data-7fcb87bd5c7cfbbdPharmaRadar360en2026-09-20T17:53:43.000ZIGM Biosciences stock trades quietly amid lack of fresh datahttps://www.pharmaradar360.com/article/spurious-drugs-karnataka-fda-cancels-16-drug-licences-of-retailers-wholesalers-483f672ee324efeePharmaRadar360en2026-09-20T17:46:14.000ZSpurious Drugs: Karnataka FDA Cancels 16 Drug Licences Of Retailers, Wholesalershttps://www.pharmaradar360.com/article/karnataka-cancels-16-drug-licences-of-retailers-wholesalers-over-spurious-medici-2c63099044d2094ePharmaRadar360en2026-09-20T16:43:00.000ZKarnataka cancels 16 drug licences of retailers, wholesalers over spurious medicineshttps://www.pharmaradar360.com/article/the-real-start-of-every-biotech-story-is-not-a-lab-but-the-funding-decision-c8c47d90798c3214PharmaRadar360en2026-09-20T16:42:25.000ZThe Real Start of Every Biotech Story is not a Lab but the Funding Decisionhttps://www.pharmaradar360.com/article/counterfeit-drug-racket-karnataka-fda-cancels-licences-of-16-firms-suspends-eigh-75a62da78792156dPharmaRadar360en2026-09-20T16:27:40.000ZCounterfeit drug racket: Karnataka FDA cancels licences of 16 firms, suspends eight others including Pfizerhttps://www.pharmaradar360.com/article/k-taka-fda-cancels-16-drug-licences-of-retailers-wholesalers-c3da9512d4ad2b56PharmaRadar360en2026-09-20T16:19:28.000ZK'taka FDA cancels 16 drug licences of retailers, wholesalershttps://www.pharmaradar360.com/article/spurious-drug-racket-busted-at-bidadi-farmhouse-rs-5-crore-stock-seized-37c1c944ca0872f9PharmaRadar360en2026-09-20T16:13:00.000ZSpurious drug racket busted at Bidadi farmhouse, Rs 5 crore stock seizedhttps://www.pharmaradar360.com/article/india-s-biotech-start-ups-need-patient-capital-to-drive-novel-drug-innovation-in-7b639daf4e308b1aPharmaRadar360en2026-09-20T16:03:20.000ZIndia’s biotech start-ups need patient capital to drive novel drug innovation, industry leaders sayhttps://www.pharmaradar360.com/article/fda-reviewing-contraceptives-tied-to-meningioma-risk-e58870d2131fdd90PharmaRadar360en2026-09-20T16:00:00.000ZFDA reviewing contraceptives tied to meningioma riskhttps://www.pharmaradar360.com/article/cheap-drugs-fake-labels-non-functional-qr-codes-karnataka-fda-cancels-16-licence-30805af09704bb40PharmaRadar360en2026-09-20T15:46:00.000ZCheap drugs, fake labels, non-functional QR codes: Karnataka FDA cancels 16 licences of retailers, wholeshttps://www.pharmaradar360.com/article/karnataka-busts-fake-drug-racket-suspends-license-of-pfizer-depot-7-other-firms-5a01456374a081c9PharmaRadar360en2026-09-20T15:39:20.000ZKarnataka busts fake drug racket, suspends license of Pfizer depot, 7 other firmshttps://www.pharmaradar360.com/article/novocure-nvcr-breaks-out-on-q2-2026-earnings-optune-pax-driving-recovery-d29aa8bbd69d100aPharmaRadar360en2026-09-20T15:34:39.000ZNovoCure (NVCR) Breaks Out on Q2 2026 Earnings - Optune Pax Driving Recoveryhttps://www.pharmaradar360.com/article/fda-cancels-16-suspends-eight-drug-licences-in-karnataka-india-news-ba30705170e35c28PharmaRadar360en2026-09-20T15:25:26.000ZFDA cancels 16, suspends eight drug licences in Karnataka | India Newshttps://www.pharmaradar360.com/article/sartorius-stedim-stock-holds-steady-as-investors-digest-recent-results-357e977aebe6ec21PharmaRadar360en2026-09-20T15:08:26.000ZSartorius Stedim stock holds steady as investors digest recent resultshttps://www.pharmaradar360.com/article/study-finds-no-neurodevelopmental-risk-in-prenatal-covid-19-except-speech-60978aa7141468f4PharmaRadar360en2026-09-20T15:06:40.000ZStudy Finds No Neurodevelopmental Risk in Prenatal COVID-19, Except Speechhttps://www.pharmaradar360.com/article/fake-drug-racket-case-why-did-karnataka-fda-take-action-against-pfizer-and-other-c891e75d1209a28ePharmaRadar360en2026-09-20T14:47:26.000ZFake drug racket case: Why did Karnataka FDA take action against Pfizer and other pharmacy establishments?https://www.pharmaradar360.com/article/retension-pharmaceuticals-trex-bio-file-for-us-ipo-as-biotech-momentum-continues-3e00c4b5d346cd8cPharmaRadar360en2026-09-20T14:41:31.000ZRetension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continueshttps://www.pharmaradar360.com/article/karnataka-16-licences-cancelled-over-suspected-fake-drug-supply-0e40f8f1294379fePharmaRadar360en2026-09-20T14:36:39.000ZKarnataka: 16 licences cancelled over suspected fake drug supplyhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-stock-holds-near-fair-value-as-valuation-debate-int-4a13daa556aa57dePharmaRadar360en2026-09-20T14:28:16.000ZWest Pharmaceutical Services stock holds near fair value as valuation debate intensifieshttps://www.pharmaradar360.com/article/what-is-drawing-attention-to-west-pharmaceutical-services-wst-92b5c124882ba4d9PharmaRadar360en2026-09-20T14:07:44.000ZWhat Is Drawing Attention To West Pharmaceutical Services (WST)?https://www.pharmaradar360.com/article/accelerating-digital-transformation-in-the-pharmaceutical-sector-61a20ba6a4cf5dbbPharmaRadar360en2026-09-20T14:06:51.000ZAccelerating digital transformation in the pharmaceutical sectorhttps://www.pharmaradar360.com/article/pharmaceutical-society-calls-for-stronger-drug-regulation-f2db6216a77cc7afPharmaRadar360en2026-09-20T14:04:22.000ZPharmaceutical Society Calls for Stronger Drug Regulationhttps://www.pharmaradar360.com/article/la-biotech-firm-innata-bio-moves-headquarters-to-philadelphia-s-lilly-gateway-la-c364a610699ace50PharmaRadar360en2026-09-20T14:00:00.000ZLA Biotech Firm Innata Bio Moves Headquarters to Philadelphia’s Lilly Gateway Labshttps://www.pharmaradar360.com/article/karnataka-fda-cancels-16-pharmacy-licences-over-spurious-drug-racket-f06b08fa08cf993bPharmaRadar360en2026-09-20T13:57:17.000ZKarnataka FDA cancels 16 pharmacy licences over spurious drug racket